Verrica Pharmaceuticals Inc. Payments of Stock Issuance Costs
Verrica Pharmaceuticals Inc. (VRCA) reported Payments of Stock Issuance Costs of $900.00 thousand for the 1-month period ending 2025-11-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. payments of stock issuance costs for the quarter ending 2024-09-30 was $163.00K, a 167.21% increase year-over-year.
- Verrica Pharmaceuticals Inc. payments of stock issuance costs for the quarter ending 2023-09-30 was $61.00K.
| Period end | Payments of Stock Issuance Costs | Payments of Stock Issuance Costs 1 month | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|---|---|
| 2025-11-30 | $900.00K 10-Q · filed 2026-08-06 | ||||
| 2025-11-23 | $900.00K 10-K · filed 2026-03-11 | ||||
| 2024-11-30 | $2.90M 10-K · filed 2026-03-11 | ||||
| 2024-11-22 | $2.90M 10-Q · filed 2025-05-13 | ||||
| 2024-09-30 | $163.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $163.00K 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | ||||
| 2023-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $173.00K 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | $112.00K 10-Q · filed 2024-08-14 | ||||
| 2023-02-28 | $2.20M 10-Q · filed 2023-08-08 | ||||
| 2023-02-23 | $2.30M 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |